Details for Patent: 8,232,280
✉ Email this page to a colleague
Title: | Inhibitors of bruton'S tyrosine kinase |
Abstract: | Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
Inventor(s): | Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX) |
Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
Filing Date: | Jan 21, 2011 |
Application Number: | 13/011,258 |
Claims: | 1. A compound having the structure: ##STR00057## wherein: A is ##STR00058## L.sub.a is CH.sub.2, O, NH or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; B is ##STR00059## Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, NRS(.dbd.O).sub.x, where x is 1 or 2; R.sub.7 and R.sub.8 are independently selected from among H, unsubstituted C.sub.1-C.sub.4 alkyl, substituted C.sub.1-C.sub.4alkyl, unsubstituted C.sub.1-C.sub.4heteroalkyl, substituted C.sub.1-C.sub.4heteroalkyl, unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted C.sub.3-C.sub.6cycloalkyl, unsubstituted C.sub.2-C.sub.6heterocycloalkyl, and substituted C.sub.2-C.sub.6heterocycloalkyl; or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); wherein R.sub.6, R.sub.7, and R.sub.8 are not all H; R is H or C.sub.1-C.sub.6alkyl; or a pharmaceutically acceptable salts thereof. 2. The compound of claim 1, wherein L.sub.a is O. 3. The compound of claim 2, wherein Ar is phenyl. 4. The compound of claim 3, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2. 5. The compound of claim 4, wherein R.sub.8 is H. 6. The compound of claim 5, wherein R.sub.6 is H. 7. The compound of claim 1 selected from among: (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)-4-(dimethylamino)but-2-en-1-one; (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)-4-methoxybut-2-en-1-one; and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)but-2-en-1-one. 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient. 9. A compound having the structure: ##STR00060## wherein: A is ##STR00061## L.sub.a is CH.sub.2, O, NH or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; B is ##STR00062## Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, NRS(.dbd.O).sub.8, where x is 1 or 2; R.sub.7 and R.sub.8 are independently selected from among H, unsubstituted C.sub.1-C.sub.4 alkyl, substituted C.sub.1-C.sub.4alkyl, unsubstituted C.sub.1-C.sub.4heteroalkyl, substituted C.sub.1-C.sub.4heteroalkyl, unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted C.sub.3-C.sub.6cycloalkyl, unsubstituted C.sub.2-C.sub.6heterocycloalkyl, and substituted C.sub.2-C.sub.6heterocycloalkyl; or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); wherein R.sub.6, R.sub.7, and R.sub.8 are not all H; R is H or C.sub.1-C.sub.6alkyl; or a pharmaceutically acceptable salts thereof. 10. The compound of claim 9, wherein L.sub.a is O. 11. The compound of claim 10, wherein Ar is phenyl. 12. The compound of claim 11, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2. 13. The compound of claim 12, wherein R.sub.8 is H. 14. The compound of claim 13, wherein R.sub.6 is H. 15. The compound of claim 9 selected from among: (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-methoxybut-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-methoxybut-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-(dimethylamino)but-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)but-2-en-1-one; (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-(dimethylamino)but-2-en-1-one and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)but-2-en-1-one. 16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable excipient. |